Buscar
Elicio Therapeutics Inc
ELTXAñadir a la lista de seguimiento
2.800USD
-0.110-3.78%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
49.84MCap. mercado
PérdidaP/E TTM
Más Datos de Elicio Therapeutics Inc Compañía
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Información de Elicio Therapeutics Inc
Símbolo de cotizaciónELTX
Nombre de la empresaElicio Therapeutics Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoConnelly (Robert)
Número de empleados32
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección451 D Street, 5Th Floor
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02459
Teléfono18572090050
Sitio Webhttps://elicio.com/
Símbolo de cotizaciónELTX
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoConnelly (Robert)
Ejecutivos de Elicio Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
-2799.46%
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
--
-100.00%
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
-2799.46%
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Elicio Therapeutics Inc?
Los cinco principales accionistas de Elicio Therapeutics Inc son: Dr. Jay R. Venkatesan, M.D.
¿Cuántas instituciones poseen acciones de Elicio Therapeutics Inc (ELTX)?
A fecha de 2026Q1, 75 instituciones poseen acciones de Elicio Therapeutics Inc, con un valor de mercado combinado de aproximadamente 2.79M, lo que representa el 15.12% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -632315.00.